



PERFORMANCE



PROTECTION



PROOF

Ethicon Plus Antibacterial Sutures

The only suture portfolio proven effective in addressing a known risk factor for surgical site infections²⁻¹⁵




Triclosan-coated sutures are an integral part of surgical care bundles that address surgical site infection (SSI)¹

Ethicon Plus Antibacterial Sutures are the only triclosan-coated sutures commercially available worldwide

Plus Sutures are the **only surgical intervention** shown to help reduce biofilm formation and bacterial colonization of the suture—a known risk factor for SSI. Their safety and efficacy are supported by a wealth of the highest-quality evidence, backed by nearly 2 decades of commercial use.²⁻¹⁵

To reduce SSI risk, trust an evidence-based strategy

Plus Sutures are supported by a wealth of Level 1A evidence, the highest quality in the Evidence-based Medicine Pyramid³⁻¹⁵:



- Meta-regression analyses demonstrated that the effect of triclosan-coated sutures in reducing the risk of SSI does not vary by CDC wound classification or suture type^{4**†}

²21 RCTs, 6,462 patients, 95% CI: (14, 40%), P<0.001.

⁴All triclosan-coated sutures in these RCTs were Ethicon Plus Antibacterial Sutures (Monocryl Plus, Vicryl Plus and PDS Plus).

[†]Clean wounds 10 RCT, 2842 patients, 95% CI (11-43%), P=0.003; non-clean wounds 14 RCT, 3620 patients, 95% CI (7-42%).

Perceptions vs facts about SSI and Plus Sutures

PERCEPTION

1 Many things can lead to an infection—suture is not my key concern

FACT

Sutures are implants and, like all implants, can increase the risk of infection once a biofilm has been established. Plus Sutures inhibit bacterial colonization of the suture which can lead to biofilm formation.^{2,3,16}

PERCEPTION

2 I am already taking measures to prevent SSI

FACT

Prophylactic antibiotic use is not always effective in preventing SSI.¹⁷ The optimal approach to preventing SSI is by using several proven interventions in care bundles. One such intervention could be Plus Sutures, which are shown to inhibit bacterial colonization of the suture for 7 days or more.¹⁸⁻²⁰

PERCEPTION

3 Use of triclosan has been banned by the FDA

FACT

Triclosan has not been banned by the FDA. The clinical benefit of triclosan, specifically in consumer antiseptic washes and healthcare handwashes, scrubs, and skin preps, was questioned. The clinical value of triclosan-coated sutures for wound closure is well-established and supported by Level 1A evidence as well as multiple evidence-based clinical practice guidelines.^{4,21-27}

PERCEPTION

4 Higher cost of Plus Sutures is not justified

FACT

At just ~60¢ more per strand, Plus Sutures are a small price to pay compared with the ~\$42,102 that a single SSI can cost.²⁸⁻³⁰

PERCEPTION

5 Evidence supporting effectiveness of Plus technology is not strong

FACT

Plus Sutures are supported by the highest level of clinical evidence (1A) and by health authorities around the world.^{4,23,27}

^{*}Based on Australian Dollars

Make Plus Sutures part of your comprehensive, evidence-based, SSI risk-reduction strategy

Recommendations you can trust

Triclosan-coated sutures are supported by evidence-based recommendations from a growing number of global health authorities as part of the SSI bundle.^{23-27,31*}

US Guidelines



AMERICAN COLLEGE OF SURGEONS
Inspiring Quality. Highest Standards. Better Outcomes



Australian Guidelines

NHMRC National Health and Medical Research Council

International Guidelines



UK Guidelines

NICE National Institute for Health and Care Excellence

German Guidelines

ROBERT KOCH INSTITUT



Go with proven protection. Plus.

For complete indications, contraindications, warnings, precautions, and adverse reactions, please reference full package insert.

*CDC, NHMRC, WHO, ACS/SIS, NICE, and RKI guidelines on reducing the risk of surgical site infections are general to triclosan-coated sutures and are not specific to any one brand.

References: 1. World Health Organization. WHO Guidelines for Safe Surgery 2009. https://apps.who.int/iris/bitstream/handle/10665/44185/9789241598552_eng.pdf?sequence=1. Accessed February 10, 2020. 2. Edmiston CE, Seabrook GR, Goheen MP, et al. Bacterial adherence to surgical sutures: can antibacterial-coated sutures reduce the risk of microbial contamination? *J Am Coll Surg*. 2006;203(4):481-489. 3. Edmiston CE, Daoud FC, Leaper D. Is there an evidence-based argument for embracing an antimicrobial (triclosan)-coated suture technology to reduce the risk for surgical-site infections?: A meta-analysis. *Surgery*. 2013;154:89-100. 4. de Jonge SW, Atema JJ, Solomkin JS, Boermeester MA. Meta-analysis and trial sequential analysis of triclosan-coated sutures for the prevention of surgical-site infection. *Br J Surg*. 2017;104(2):e118-e133. 5. Leaper DJ, Edmiston CE Jr, Holy CE. Meta-analysis of the potential economic impact following introduction of absorbable antimicrobial sutures. *Br J Surg*. 2017;104(2):e134-e144. 6. Apisarnthanarak A, Singh N, Bandong AN, et al. Triclosan-coated sutures reduce the risk of surgical site infections: a systematic review and meta-analysis. *Infect Control Hosp Epidemiol*. 2015;36:169-179. 7. Chang WK, Srinivasa S, Morton R, et al. Triclosan-impregnated sutures to decrease Surgical Site Infections: Systematic Review and Meta-Analysis of Randomized Trials. *Ann Surg*. 2012;255(5):854-859. 8. Daoud FC, Edmiston CE Jr, Leaper D. Meta-analysis of prevention of surgical site infections following incision closure with triclosan-coated sutures: robustness to new evidence. *Surg Infect (Larchmt)*. 2014;15(3):165-181. 9. Daoud FC. Systematic literature review update of the PROUD Trial: potential usefulness of a collaborative database. *Surg Infect (Larchmt)*. 2014;15(6):857-858. 10. Guo J, Pan LH, Li YX, et al. Efficacy of triclosan-coated sutures for reducing risk of surgical site infection in adults: a meta-analysis of randomized clinical trials. *J Surg Res*. 2016; 201(1):105-117. 11. Sajid MS, Craciunas L, Sains P, et al. Use of antibacterial sutures for skin closure in controlling surgical site infections: a systematic review of published randomized, controlled trials. *Gastroenterol Rep (Oxf)*. 2013;1(1):42-50. 12. Sandini M, Mattavelli I, Nespoli L, Uggeri F, Gianotti L. Systematic review and meta-analysis of sutures coated with triclosan for the prevention of surgical site infection after elective colorectal surgery according to the PRISMA statement. *Medicine (Baltimore)*. 2016;95(35):e4057. 13. Wang ZX, Jiang CP, Cao Y, et al. Systematic review and meta-analysis of triclosan-coated sutures for the prevention of surgical-site infection. *Brit J Surg*. 2013;100(4): 465-473. 14. Wu X, Kubilay NZ, Ren J, et al. Antimicrobial-coated sutures to decrease surgical site infections: a systematic review and meta-analysis. *Eur J Clin Microbiol Infect Dis*. 2017;36(1):19-32. 15. Ahmed I, Boulton AJ, Rizvi S, et al. The use of triclosan-coated sutures to prevent surgical site infections: a systematic review and meta-analysis of the literature. *BMJ Open*. 2019;9:e029727. doi:10.1136/bmjopen-2019-029727. 16. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Hospital Infection Control Practices Advisory Committee. Guideline for Prevention of Surgical Site Infection, 1999. *Infect Control Hosp Epidemiol*. 1999;20(4):250-278. 17. Nakamura T, Kashimura N, Noji T, et al. Triclosan-coated sutures reduce the incidence of wound infections and the costs after colorectal surgery: A randomized controlled trial. *Surgery*. 2013;153(4):576-583. 18. Ming X, Rothenburger S, Yang D. In vitro antibacterial efficacy of Monocryl Plus Antibacterial Suture (poliglecaprone 25 with triclosan). *Surg Infect (Larchmt)*. 2007;8(2):201-207. 19. Rothenburger S, Spangler D, Bhende S, Burkley D. In vitro antimicrobial evaluation of coated Vicryl Plus Antibacterial Suture (coated polyglactin 910 with triclosan) using zone of inhibition assays. *Surg Infect (Larchmt)*. 2002;3(suppl):S79-S87. 20. Ming X, Rothenburger S, Nichols MM. In vivo and in vitro antibacterial efficacy of PDS Plus (polydioxanone with triclosan) suture. *Surg Infect (Larchmt)*. 2008;9(4):451-457. 21. Food and Drug Administration. Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use. *Federal Register*. 2016. <https://www.federalregister.gov/documents/2016/09/06/201621337/safety-and-effectiveness-of-consumer-antiseptics-topical-antimicrobial-drug-products-for>. Accessed February 6, 2020. 22. Food and Drug Administration. Safety and Effectiveness of Health Care Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use. *Federal Register*. 2017. <https://www.federalregister.gov/documents/2017/12/20/201727317/safety-and-effectiveness-of-health-care-antiseptics-topical-antimicrobial-drug-products-for>. Accessed February 6, 2020. 23. Berrios-Torres SI, Umscheid CA, Bratzler DW, et al. Centers for Disease Control and Prevention Guideline for the Prevention of Surgical Site Infection. *JAMA Surg*. 2017;152(8):784-791. doi:10.1001/jamasurg.2017.0904. 24. World Health Organization. Global Guidelines for the Prevention of Surgical Site Infection. <https://apps.who.int/iris/bitstream/handle/10665/250680/9789241549882-eng.pdf?sequence=8>. Published November 2016. Accessed February 10, 2020. 25. Ban KA, Minei JP, Laronga C, et al. American College of Surgeons and Surgical Infection Society. Surgical Site Infection Guidelines, 2016 Update. *J Am Coll Surg*. 2016;224(1):59-74. 26. National Institute for Health and Care Excellence (NICE) Guideline. Surgical site infections: prevention and treatment. NICE website. <https://www.nice.org.uk/guidance/ng125/chapter/Recommendations#closuremethods>. Accessed October 17, 2019. 27. Prevention of postoperative wound infections. Recommendation of the Committee for Hospital Hygiene and Infection Prevention (KRINKO) at the Robert Koch Institute. *Bundesgesundheitsbl*. 2018; 61(4):448-473. 28. Plus Suture Cost Analysis. 2019. Ethicon, Inc. 29. de Lissovoy G, Pan F, Patkar A, et al. Surgical Site Infection Incidence and Burden Assessment Using Multi-institutional Real-world Data. 2011. Ethicon, Inc. 30. Plus Suture Cost Analysis. 2019. Ethicon, Inc. 31. Australian Guidelines for the Prevention and Control of Infection in Healthcare, Canberra: National Health and Medical Research Council (2019).